The makings of a tumor rejection antigen
E Gilboa - Immunity, 1999 - cell.com
The recognition that tumors could after all be suffiin the annals of contemporary cancer
immunotherapy. ciently “foreign” to be recognized by the immune system There are three …
immunotherapy. ciently “foreign” to be recognized by the immune system There are three …
Immunotherapy of cancer with dendritic-cell-based vaccines
E Gilboa, SK Nair, HK Lyerly - Cancer Immunology, Immunotherapy, 1998 - Springer
Animal studies have shown that vaccination with genetically modified tumor cells or with
dendritic cells (DC) pulsed with tumor antigens are potent strategies to elicit protective …
dendritic cells (DC) pulsed with tumor antigens are potent strategies to elicit protective …
Engineered nucleic acids encoding a modified erythropoietin and their expression
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
46147671&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
46147671&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo.
D Boczkowski, SK Nair, D Snyder… - The Journal of …, 1996 - rupress.org
Immunization with defined tumor antigens is currently limited to a small number of cancers
where candidates for tumor rejection antigens have been identified. In this study we …
where candidates for tumor rejection antigens have been identified. In this study we …
Terminally modified RNA
T Chakraborty, S Bancel, SG Hoge, A Roy… - US Patent …, 2017 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49447811&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
49447811&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens
V Lennerz, M Fatho, C Gentilini… - Proceedings of the …, 2005 - National Acad Sciences
Our understanding of pathways leading to antitumor immunity may depend on an
undistorted knowledge of the primary antigenic targets of patients' autologous T cell …
undistorted knowledge of the primary antigenic targets of patients' autologous T cell …
Engineered nucleic acids and methods of use thereof
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C (= O) C (NC (= O)
C (CCC (N)= O) NC (= O) C (CCC (O)= O) NC (= O) C (C (C) C) NC (= O) C (NC (= O) CN) C …
C (CCC (N)= O) NC (= O) C (CCC (O)= O) NC (= O) C (C (C) C) NC (= O) C (NC (= O) CN) C …
Modified polynucleotides for the production of biologics and proteins associated with human disease
S Bancel, T Chakraborty, A De Fougerolles… - US Patent …, 2015 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
Modified polynucleotides for the production of secreted proteins
T Chakraborty, A De Fougerolles - US Patent 9,192,651, 2015 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions
F Von Der Mülbe, I Hoerr, S Pascolo - US Patent 10,188,748, 2019 - Google Patents
The present invention relates to a pharmaceutical composi tion comprising a modified
mRNA that is stabilized by sequence modifications and optimized for translation. The …
mRNA that is stabilized by sequence modifications and optimized for translation. The …